Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Renaissance Technologies LLC grew its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 56.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,100 shares of the biopharmaceutical company’s stock after purchasing an additional 42,600 shares during the quarter. Renaissance Technologies LLC owned about 0.18% of Regulus Therapeutics worth $211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rhumbline Advisers bought a new stake in Regulus Therapeutics in the second quarter worth approximately $136,000. Bank of New York Mellon Corp bought a new stake in shares of Regulus Therapeutics in the 2nd quarter valued at $352,000. Opaleye Management Inc. acquired a new position in shares of Regulus Therapeutics during the 1st quarter valued at $490,000. RA Capital Management L.P. bought a new position in Regulus Therapeutics during the first quarter worth $18,000,000. Finally, NEA Management Company LLC acquired a new stake in Regulus Therapeutics in the first quarter worth $18,627,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Stock Performance

RGLS stock opened at $1.52 on Friday. The business has a 50-day simple moving average of $1.60 and a two-hundred day simple moving average of $1.98. The company has a market capitalization of $99.51 million, a P/E ratio of -1.04 and a beta of 1.62. Regulus Therapeutics Inc. has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.17). As a group, sell-side analysts forecast that Regulus Therapeutics Inc. will post -0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on RGLS. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. Canaccord Genuity Group increased their price target on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Tuesday, October 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to MarketBeat, Regulus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.